38
Participants
Start Date
June 11, 2021
Primary Completion Date
May 17, 2022
Study Completion Date
July 12, 2022
BBT-401-1S or Placebo
Administered by 200mg capsules of BBT-401-1S or placebo
Intercity Gastroentertology, Fresh Meadows
Korea University Ansan Hospital, Ansan
Communal Non-profit enterprise Vinnytsya city clinical hospital 1 gastroenterology department, Vinnytsia
Medical Center of LLC Oxford Medical-Vinnytsia, Vinnytsia
Wonju Severance Christian Hospital, Wŏnju
Javara Research, Charlotte
Kyungpook National University Chilgok Hospital, Bugok
Yeungnam University Hospital, Daegu
Municipal Enterprise Volyn Regional Clinical Hospital of the Volyn Regional Council, Department of S, Luts'k
Inje University Haeundae Paik Hospital, Haeundae
Municipal Non-Profit Enterprise City Clinical Hospital No. 2 named after prof. O.O. Shalimov of the, Kharkiv
Premier Gastroenterology, Little Rock
Premier Gastroenterology, Little Rock
Municipal Non-Profit Enterprise Kherson City Clinical Hospital named after E.E.Karabelesha of Kherso, Kherson
Inves Clinic, McAllen
Discovery Clinical Trials - AACT, Pflugerville
Velocity Clinical Research, Riverton
West Jordan, West Jordan
Saini Surinder S MD, Fountain Valley
Gastro Care Institute, Lancaster
Centrum Medyczne Pratia Bydgoszcz, Bydgoszcz
VITA LONGA Sp. z o.o., Katowice
Centrum Medyczne Melita Medical, Wroclaw
Uniwersytecki Szpital Kliniczny Nr. 1 im. Norberta Barlickiego, Lodz
Inje University, Seoul Paik Hospital, Junggu
The Catholic university of Korea, Seoul St Mary's Hospital, Seocho
Medical Centre of the Limited Liability Company Medical Clinic Blagomed, Treatment and Diagnostic Di, Kyiv
Communal Non-profit enterprise Kyiv City Clinical Hospital No. 18, of the executive body of the Kyiv, Kyiv
Medical Center RCLIN Ukraine of the Limited Liability Company Cardiocom, Obukhiv
Municipal Non-Profit Enterprise of the Kyiv Regional Council Kyiv Regional Hospital, Therapeutics De, Kyiv
Lead Sponsor
Collaborators (1)
Covance
INDUSTRY
Bridge Biotherapeutics, Inc.
INDUSTRY